Issuance of new us patent bolsters ip protection for jaguar health in the treatment of congenital diarrheal disorders (cdds)

New patent issued for core rare disease target indication for crofelemer jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease - an ultrarare cdd - and short bowel syndrome (sbs) in the us, eu, and middle east/north africa regions, with results expected in 2024 san francisco, ca / accesswire / january 4, 2024 / napo pharmaceuticals (napo), a jaguar health (nasdaq:jagx) (jaguar) family company, today announced that the united states patent and trademark office on january 2, 2024 issued a new u.s. patent to napo for methods for treating congenital diarrheal disorders (cdds) in patients with an inhibitor of chloride-ion transport such as crofelemer, napo's novel plant-based prescription drug. "we are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core focus on cdd indications," said lisa conte, jaguar's founder, president, and ceo.
JAGX Ratings Summary
JAGX Quant Ranking